임상시험 매칭 소프트웨어 시장 : 시장 예측(2026-2032년)

The Clinical Trials Matching Software Market is projected to grow by USD 512.60 million at a CAGR of 13.35% by 2032.

Clinical trials matching software is becoming a critical digital layer in clinical research, connecting eligible participants with appropriate studies through structured eligibility criteria, electronic health records, patient registries, genomic data, laboratory values, imaging outputs, physician referrals, and patient-reported information. The need is well documented: many clinical trials face recruitment delays, eligibility criteria are increasingly complex, and sponsors, research sites, healthcare providers, and patient advocacy networks require faster, more accurate ways to identify trial-ready populations. Modern clinical trial matching platforms support protocol feasibility, prescreening, referral management, decentralized trial recruitment, oncology trial matching, rare disease enrollment, and real-world data activation while helping reduce manual chart review and avoidable enrollment friction. Demand is especially strong around AI clinical trial matching, patient recruitment software, clinical trial enrollment technology, EHR-based trial matching, precision medicine trials, and decentralized clinical trial platforms. As regulators and health authorities continue emphasizing diversity, transparency, patient centricity, and evidence quality, matching software is shifting from a recruitment support tool to an operational intelligence system that improves trial access, site productivity, and study execution. Transformative Shifts in Clinical Trial Matching

The clinical trials matching software landscape is being reshaped by the convergence of healthcare digitization, precision medicine, decentralized research models, and stronger expectations for participant diversity. Trial protocols increasingly include molecular markers, prior therapy lines, comorbidities, imaging findings, and biomarker-defined subgroups, making manual eligibility review less scalable and more prone to inconsistency. At the same time, healthcare systems are expanding the use of electronic health records, laboratory information systems, imaging repositories, claims data, patient portals, and clinical registries, creating new opportunities for automated patient identification when privacy, consent, and interoperability requirements are met. Another major shift is the movement of clinical research closer to routine care. Rather than relying only on dedicated research centers, trial matching is being embedded into care pathways so physicians can identify relevant studies during diagnosis, treatment planning, and follow-up. Decentralized and hybrid trial designs are also influencing software requirements, increasing demand for geolocation matching, remote consent workflows, multilingual patient engagement, telehealth integration, and screening logistics. In parallel, the push for representative clinical trials is making demographic, socioeconomic, geographic, and disease-burden analytics more important. These shifts are creating a more connected, patient-centered, and data-driven recruitment ecosystem.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact on clinical trials matching software by improving how unstructured and structured clinical data are interpreted, ranked, and operationalized. Natural language processing can extract meaningful details from physician notes, pathology reports, radiology narratives, discharge summaries, and genomic interpretations, helping identify eligibility indicators that are not always captured in structured fields. Machine learning models can prioritize likely eligible participants, detect protocol feasibility risks, recommend sites with relevant patient populations, and support continuous matching as patient data change over time. Generative AI and large language model capabilities are also being explored to translate protocol eligibility criteria into computable logic, summarize trial options for clinicians, and simplify patient-facing study descriptions. However, clinical AI adoption must remain governed by validated performance, explainability, bias assessment, privacy protection, auditability, and human oversight. The most effective AI-enabled trial matching systems combine algorithmic screening with clinical review, regulatory-grade documentation, consent-aware data use, and integrations into existing healthcare workflows. As a result, artificial intelligence is not replacing research professionals; it is enabling them to screen larger patient populations with greater speed, consistency, and traceability.

Key Regional Insights

Asia-Pacific is emerging as a high-priority region for clinical trials matching software due to expanding clinical research activity, large and diverse patient populations, growing digital health investment, and increasing adoption of electronic medical records across China, India, Japan, South Korea, Australia, and Southeast Asian markets. The region's complexity creates strong demand for multilingual platforms, local regulatory alignment, hospital network integration, and disease-area customization, particularly in oncology, infectious diseases, metabolic disorders, cardiovascular conditions, and rare diseases. Europe demonstrates strong demand for interoperable, privacy-centered trial matching platforms, with the General Data Protection Regulation shaping consent management, data minimization, lawful processing, and cross-border research workflows, while the region's clinical trial regulation framework supports greater transparency and harmonized submissions. North America remains one of the most mature environments for clinical trial matching technology, supported by advanced EHR penetration, established research infrastructure, extensive academic medical center participation, strong patient advocacy networks, and regulatory emphasis on trial modernization, decentralized approaches, and enrollment diversity. Latin America, particularly Brazil and Mexico, is gaining attention for patient recruitment potential, treatment-naive populations in selected therapeutic areas, and improving research site capabilities, though uneven digital infrastructure, ethics approval timelines, and institutional readiness can affect implementation. Africa presents meaningful long-term potential due to high disease burden, population diversity, and expanding clinical research interest, but adoption depends on strengthening digital records, connectivity, regulatory capacity, research workforce development, and site readiness. The Middle East is investing in digital health, genomics, specialty care infrastructure, and national health data strategies, creating opportunities for software that supports research partnerships, registry activation, and privacy-aware patient matching across advanced hospital systems.

Key Group Insights

NATO member countries overlap significantly with developed research markets in North America and Europe, where cybersecurity, data sovereignty, operational resilience, and trusted health data exchange are increasingly important for deploying clinical trials matching software across hospitals, research institutions, defense health systems, and public health networks. G7 countries generally provide mature clinical research ecosystems, high healthcare spending, sophisticated academic networks, strong regulatory expectations, and broad digital health infrastructure, supporting advanced AI-based matching, EHR integration, real-world data linkage, and diversity analytics. BRICS countries offer a combination of scale, therapeutic diversity, expanding hospital digitization, and growing research infrastructure, with China, India, Brazil, and South Africa presenting substantial patient access opportunities and Russia maintaining clinical research capabilities shaped by local regulatory and geopolitical considerations. The European Union is a key environment for privacy-preserving, interoperable clinical trial matching because harmonized clinical research rules, data protection obligations, cross-border research collaboration, and multilingual patient engagement require platforms capable of secure data exchange, consent documentation, and audit-ready workflows. ASEAN markets are increasingly relevant as member countries expand healthcare digitization, regional research collaboration, and access to diverse patient populations, while requiring localized language support, site enablement, adaptable consent workflows, and flexible implementation models suited to varied digital maturity. GCC countries are advancing national digital health initiatives, precision medicine programs, genomics strategies, and hospital modernization, making the group attractive for clinical trial recruitment platforms that can connect specialty centers, registries, and genomic data under strong privacy and governance frameworks.

Key Country Insights

China is advancing rapidly through hospital digitization, oncology research, genomics, and large patient populations, while requiring strict localization, cybersecurity compliance, and alignment with national data governance requirements. The United States is a leading adopter of clinical trials matching software due to extensive clinical research activity, broad EHR utilization, large specialty care networks, strong oncology and rare disease programs, and ongoing efforts to improve enrollment diversity and reduce recruitment delays. Japan's aging population, advanced medical system, precision medicine focus, and established clinical research standards support demand for high-quality trial matching that can address complex inclusion criteria and longitudinal patient data. India combines substantial disease burden, expanding digital health infrastructure, a large patient base, and rising hospital participation in research, creating opportunities for scalable, multilingual matching tools that support urban and regional site networks. Germany, the United Kingdom, France, Italy, and Spain each provide established clinical research capacity, advanced hospitals, and strong regulatory oversight, with demand shaped by interoperability, data protection, specialty network participation, and the need to operationalize EHR-linked patient identification. Australia offers strong research governance, diverse trial participation, and Asia-Pacific connectivity, making it well positioned for decentralized recruitment, registry-driven matching, and cross-border study collaboration. South Korea is notable for advanced hospital IT systems, strong oncology research, high digital readiness, and sophisticated clinical data environments, making it a strong setting for AI-enabled patient matching. Canada supports adoption through integrated healthcare systems, academic research networks, and emphasis on equitable access, while requiring alignment with provincial privacy requirements and bilingual engagement in relevant regions. Russia maintains scientific and clinical research expertise, but international collaboration and technology implementation can be affected by geopolitical, regulatory, and operational constraints. Brazil offers one of Latin America's most important clinical research environments, supported by large population scale and therapeutic diversity, though digital maturity varies across institutions. Mexico is gaining relevance for recruitment efficiency and proximity to North American research operations, with opportunities tied to site modernization, patient access, and stronger digital workflow integration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize interoperability with EHRs, registries, laboratory systems, imaging repositories, eConsent tools, clinical trial management systems, and trial registries to reduce workflow friction and accelerate patient identification. Platforms should be designed around configurable eligibility logic, natural language processing, multilingual patient engagement, site referral tracking, real-time trial status updates, and computable protocol criteria. To build trust, vendors and adopters should implement transparent AI governance, bias testing, clinical validation, role-based access, audit trails, cybersecurity controls, and privacy-by-design architecture. Research organizations should also embed trial matching into routine care workflows so physicians can review relevant study options during patient encounters instead of relying solely on retrospective recruitment campaigns. To support trial diversity, leaders should incorporate demographic analytics, geographic access mapping, community-based referral pathways, decentralized screening options, and culturally appropriate communication. For global deployment, solutions must accommodate local regulations, consent models, terminology standards, language requirements, data residency expectations, and institutional review processes. Commercial and operational teams should focus on measurable outcomes such as reduced manual prescreening time, improved referral quality, faster enrollment workflows, better protocol feasibility assessment, stronger site engagement, and increased access for underrepresented participants. The strongest strategies will combine clinical credibility, technical interoperability, regulatory compliance, and patient-centered design.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public-domain and institutionally recognized sources, including regulatory guidance, clinical research policy documents, peer-reviewed literature, public health agency publications, clinical trial registry information, standards organization materials, and healthcare digitization references. The analysis emphasizes qualitative market dynamics rather than market sizing, market share, or forecasting. Key themes were evaluated across technology adoption, clinical workflow needs, regional regulatory environments, data privacy requirements, EHR interoperability, decentralized trial operations, AI governance, patient recruitment barriers, and diversity requirements. Regional, group, and country insights were synthesized by examining clinical research infrastructure, digital health maturity, population health factors, privacy rules, and trial modernization trends. The methodology applies triangulation across multiple source categories to reduce reliance on single-source claims and to ensure that conclusions are grounded in observable industry developments. Findings are framed for executive decision-making, with attention to operational relevance, implementation risks, and strategic opportunities in clinical trial matching software.

Conclusion

Clinical trials matching software is becoming an essential enabler of faster, more inclusive, and more precise clinical research. The sector is being driven by the increasing complexity of trial eligibility criteria, expansion of digital health records, adoption of decentralized and hybrid trial models, and the need to improve patient access to appropriate studies. Artificial intelligence, particularly natural language processing and machine learning, is strengthening the ability to identify eligible participants, assess feasibility, and support clinical decision-making, provided that systems remain transparent, validated, secure, and clinically supervised. Regional opportunities vary significantly: North America and Europe emphasize mature infrastructure, privacy, and interoperability; Asia-Pacific offers scale and digital acceleration; Latin America, the Middle East, and Africa present growing potential tied to site development, research capacity, and health system digitization. Industry leaders that align trial matching platforms with clinical workflows, regulatory expectations, diversity goals, and patient-centered engagement will be best positioned to improve recruitment performance and strengthen the future of evidence generation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Clinical Trials Matching Software Market, by Software Type

• 7.1. Introduction
• 7.2. Patient-Centric Matching Software
• 7.3. Trial-Centric Matching Software

8. Clinical Trials Matching Software Market, by Business Model

• 8.1. Introduction
• 8.2. Pay-for-Performance
• 8.3. Subscription-Based

9. Clinical Trials Matching Software Market, by Technology Type

• 9.1. Introduction
• 9.2. Artificial Intelligence & Machine Learning
• 9.3. Big Data Analytics
• 9.4. Blockchain
• 9.5. Natural Language Processing

10. Clinical Trials Matching Software Market, by Therapeutic Area

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
• 10.3. Infectious Diseases
• 10.4. Metabolic Disorders
• 10.5. Neurological Disorders
• 10.6. Oncology
• 10.7. Rare Disease

11. Clinical Trials Matching Software Market, by Deployment

• 11.1. Introduction
• 11.2. Cloud
• 11.3. On-Premise

12. Clinical Trials Matching Software Market, by End-Use

• 12.1. Introduction
• 12.2. Clinical Research Organizations
• 12.3. Hospitals & Academic Research Centers
• 12.4. Medical Device Firms
• 12.5. Pharmaceuticals & Biotechnology Companies

13. Clinical Trials Matching Software Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Clinical Trials Matching Software Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Clinical Trials Matching Software Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Advarra, Inc.
• 17.2. Antidote Technologies, Inc.
• 17.3. AQ, Inc
• 17.4. AutoCruitment LLC
• 17.5. BBK Worldwide, LLC by Publicis Health company
• 17.6. BEKhealth Corporation
• 17.7. Belongtail Ltd.
• 17.8. Carebox Healthcare Solutions, Inc.
• 17.9. Clara Health by M&B Sciences Inc.
• 17.10. Clariness GmbH
• 17.11. Clario
• 17.12. ClinicalConnection, Inc.
• 17.13. CSSi
• 17.14. Deep 6 AI Inc.
• 17.15. Elligo Health Research, Inc.
• 17.16. Evidation Health, Inc.
• 17.17. Formation Bio, Inc.
• 17.18. HCL Technologies Limited
• 17.19. HealthMatch Pty. Ltd.
• 17.20. ICON plc
• 17.21. Inato
• 17.22. Inspirata, Inc.
• 17.23. International Business Machines Corporation
• 17.24. IQVIA Holdings Inc.
• 17.25. Lokavant, Inc.
• 17.26. Medable Inc.
• 17.27. Medidata by Dassault Systemes SE
• 17.28. Medocity, Inc.
• 17.29. Microsoft Corporation
• 17.30. Parexel International Corporation
• 17.31. PatientWing
• 17.32. Science 37, Inc. by eMed, LLC
• 17.33. Science4Tech Solutions, S.L.
• 17.34. Sumatosoft LLC
• 17.35. Syneos Health, Inc.
• 17.36. Teckro, Inc.
• 17.37. Tempus Labs, Inc.
• 17.38. Trialbee AB
• 17.39. TrialHub by FindMeCure Ltd.
• 17.40. Veeva Systems Inc.
• 17.41. Worldwide Clinical Trials